Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences Inc (NASDAQ: CSTL) develops molecular diagnostic tests that guide cancer treatment decisions through gene expression profiling. The company's news flow centers on clinical validation studies, regulatory milestones, and commercial adoption of its diagnostic products.
Key news categories for Castle Biosciences include FDA regulatory developments such as breakthrough device designations, new test launches expanding the company's diagnostic portfolio, and peer-reviewed clinical study publications demonstrating test performance. The company regularly reports ordering volume milestones that indicate market adoption, as well as payer coverage decisions that affect reimbursement.
Quarterly earnings announcements provide insight into test volume growth across the DecisionDx-Melanoma, DecisionDx-UM, and TissueCypher product lines. Partnership and licensing agreements signal strategic expansion into new diagnostic areas. Scientific conference presentations at dermatology, oncology, and gastroenterology meetings often precede published research findings.
Follow Castle Biosciences news to track developments in precision oncology diagnostics, including clinical evidence supporting gene expression testing in melanoma and Barrett's esophagus, regulatory pathways for diagnostic devices, and the commercial trajectory of molecular testing adoption in cancer care.
Castle Biosciences (CSTL) reported a 53% increase in Q2 2022 revenue to $34.8 million, alongside a 57% rise in total test reports delivered. The firm raised its full-year revenue guidance to $130–135 million. Key test volumes included 7,125 DecisionDx-Melanoma reports, up 39%, and 1,344 DecisionDx-SCC reports, up 71%. Despite positive revenue growth, net loss for Q2 was $(1.6) million, an improvement from $(8.8) million in 2021. Cash and equivalents stood at $273 million as of June 30, 2022.
Castle Biosciences (NASDAQ: CSTL) announced that the American Gastroenterological Association recognizes its TissueCypher® Barrett’s Esophagus test as beneficial for risk stratification in patients with non-dysplastic Barrett’s esophagus. This test aims to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). The AGA's best practice advice highlights the potential of TissueCypher to enhance clinical decision-making, identifying high-risk patients who may benefit from tailored treatment plans. This represents a significant advancement in managing Barrett’s esophagus.
Castle Biosciences (NASDAQ: CSTL) is set to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:00 p.m. Eastern time. The presentation will be led by
Castle Biosciences, Inc. (CSTL) will release its financial results for Q2 and six months ending June 30, 2022, after market close on August 8, 2022. A conference call to discuss the results is scheduled for 4:30 p.m. Eastern Time on the same day. The webcast will be available on the company's Investor Relations page. Castle specializes in diagnostics, focusing on innovative tests for skin cancers and other conditions, with ongoing research in new test developments.
Castle Biosciences (NASDAQ: CSTL) announces a milestone of over 100,000 orders for its DecisionDx-Melanoma test. This test assists in guiding treatment decisions for patients diagnosed with cutaneous melanoma. Since its launch, more than 105,000 tests have been ordered by over 10,200 providers. The test's clinical utility is backed by over 35 peer-reviewed publications and has shown a 27% improvement in melanoma-specific survival in recent studies. The company's commitment to transforming patient care continues to drive its innovations in diagnostics.
Castle Biosciences (NASDAQ: CSTL) announced a presentation on its DecisionDx-Melanoma test at the 2022 American Academy of Dermatology Innovation Academy in Vancouver, Canada, from July 21-24. The test assesses individual risk for sentinel lymph node positivity and melanoma recurrence using a 31-gene expression profile. Dr. Aaron Farberg will discuss how this test aids in decision-making and improves patient outcomes. Over 97,288 tests have been ordered as of March 31, 2022, showing significant engagement and validation in melanoma management.
Castle Biosciences (Nasdaq: CSTL) reported findings from a study on uveal melanoma patients' attitudes towards prognostic testing with DecisionDx-UM. The research, presented at the 20th International Society of Ocular Oncology congress, showed that 90% of 177 surveyed patients desired prognostic information at diagnosis. Notably, there was no significant difference in decision regret among varying risk classifications (Class 1A, 1B, Class 2). Patients appreciated the insights gained from the test, including better understanding of their disease and personalized treatment options.
Castle Biosciences (CSTL) announced new findings demonstrating that its tests, DecisionDx-Melanoma and DecisionDx-SCC, can significantly improve patient management in skin cancer treatment. A pooled analysis revealed that DecisionDx-Melanoma effectively identifies high-risk melanoma patients among traditionally low-risk groups, with a notable difference in 3-year recurrence-free survival rates (75.9% vs. 97.7%). Additionally, a survey of dermatologic clinicians indicated that DecisionDx-SCC results can lead to risk-aligned treatment adjustments. The lab workflow for MyPath Melanoma and DecisionDx DiffDx-Melanoma achieved over 99% reporting of actionable results.
Castle Biosciences (CSTL) has partnered with Oregon Health & Science University in the War on Melanoma, a public health initiative aimed at early detection and prevention of melanoma. This collaboration supports education and awareness programs, including the Start Seeing Melanoma campaign and the Skin Crew, which involves professionals identifying potential skin cancer signs. Castle emphasizes the importance of early diagnosis in improving patient outcomes. The company continues to focus on innovative tests to enhance patient care and disease management.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
